Program
Cilostazol
Also written as “Cilostazol 100 mg”, “Cilostazol 50 mg Tablets” and “Cilostazol Tablet 100 mg”.
Its studies are mostly in Intermittent Claudication · Cerebral Infarction · Angina Pectoris, Variant · Raynaud Disease · Hypercholesterolemia, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 160 open or running | phase 4since Nov 7, 2002 | Nov 7, 2002 | none ahead |
| Genovate Biotechnology | 50 open or running | phase 3since Mar 13, 2025 | Mar 5, 2019 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Mutual Pharmaceutical | 20 open or running | phase 1since May 24, 2008 | May 24, 2008 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Feb 5, 2009 | Feb 5, 2009 | none ahead |
| Novartis | 10 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Viatris | 10 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
Also a collaborator on its studies: zhejiang-otsuka-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Nov 7, 2002.
- Jan 14, 20092 phase 4 studiesOtsuka · NCT00823849, NCT00823875
- Feb 5, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00838630, NCT00839930
- Apr 13, 2009Novartis's first study: phase 1 study in PainNew to NovartisNovartis · NCT00881231 · 26 enrolled
- Feb 24, 2010Phase 4 study in PolyneuropathiesOtsuka · NCT01076478 · 47 enrolled · Philippines
- Apr 21, 2010Phase 4 study in Diabetic NephropathiesOtsuka · NCT01252056 · 353 enrolled · China
- Jun 10, 2010Phase 2 study in Peripheral Arterial DiseaseOtsuka · NCT01142284 · 80 enrolled · Korea, Republic of
- Feb 17, 2014Phase 3 study in Angina Pectoris, VariantOtsuka · NCT02087007 · 100 enrolled · Korea, Republic of
- Mar 20, 2014Phase 3 study in Angina Pectoris, VariantOtsuka · NCT02094469 · 65 enrolled · Korea, Republic of
- Mar 25, 2014Phase 4 study in HypercholesterolemiaOtsuka · NCT02098460 · 300 enrolled · China
- Mar 5, 2019Genovate Biotechnology's first study: phase 1 study in Intermittent ClaudicationNew to Genovate BiotechnologyGenovate Biotechnology · NCT03864666 · 28 enrolled · United States
- Dec 10, 2021Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT05191862 · 19 enrolled · United States
- Jul 18, 2022Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT05466734 · 25 enrolled · United States
- Dec 4, 2023Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT06167265 · 40 enrolled · United States
- Mar 13, 2025Phase 3 study in Intermittent ClaudicationGenovate Biotechnology · NCT06886620 · 14 enrolled · Taiwan
TargetBeta
“Phosphodiesterase 3A inhibitor”ChEMBL 37, by rule
Other programs on PDE3A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensifentrinerule | Merck | phase 3 | 17 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06886620Intermittent Claudication · Taiwan | 3 | Terminated | Genovate Biotechnology | Feb 8, 2017 | 14 |
| NCT06167265Intermittent Claudication · United States | 1 | Completed | Genovate Biotechnology | Dec 22, 2023 | 40 |
| NCT05466734Intermittent Claudication · United States | 1 | Completed | Genovate Biotechnology | Aug 23, 2022 | 25 |
| NCT05191862Intermittent Claudication · United States | 1 | Terminated | Genovate Biotechnology | May 4, 2022 | 19 |
| NCT03864666Intermittent Claudication · United States | 1 | Completed | Genovate Biotechnology | Mar 19, 2019 | 28 |
| NCT02098460Hypercholesterolemia · China | 4 | Completed | Otsuka | Mar 2016 | 300 |
| NCT02094469Angina Pectoris, Variant · Korea, Republic of | 3 | Completed | Otsuka | Jan 2016 | 65 |
| NCT02087007Angina Pectoris, Variant · Korea, Republic of | 3 | Completed | Otsuka | Jul 2015 | 100 |
| NCT01142284Peripheral Arterial Disease · Korea, Republic of | 2 | Completed | Otsuka | Nov 29, 2012 | 80 |
| NCT01252056Diabetic Nephropathies · China | 4 | Completed | Otsuka | Dec 2012 | 353 |
| NCT01076478Polyneuropathies · Philippines | 4 | Completed | Otsuka | 47 | |
| NCT00881231Pain | 1 | Completed | Novartis | Feb 2004 | 26 |
| NCT00839930Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Feb 2004 | 30 |
| NCT00838630Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Nov 2003 | 36 |
| NCT00823875Atherosclerosis Cerebral Infarction · China | 4 | Completed | Otsuka | Dec 2009 | 200 |
| NCT00823849Diabetes Mellitus, Type 2 · China | 4 | Completed | Otsuka | Aug 2009 | 200 |
| NCT00773630Intermittent Claudication · Germany | 1 | Completed | Otsuka | Mar 2009 | 44 |
| NCT00766545Cerebral Infarction · Japan | 3 | Completed | Otsuka | Mar 1997 | 1,095 |
| NCT00685802Therapeutic Equivalency, Healthy | 1 | Completed | Mutual Pharmaceutical | Jul 2004 | 32 |
| NCT00684762Therapeutic Equivalency | 1 | Completed | Mutual Pharmaceutical | Mar 2004 | 32 |
| NCT00648388Healthy · United States | 1 | Completed | Viatris | May 2004 | 44 |
| NCT00602407Intermittent Claudication · United States | – | Completed | Hikma Pharmaceuticals | Mar 2004 | 36 |
| NCT00602173Intermittent Claudication · United States | – | Completed | Hikma Pharmaceuticals | May 2003 | 32 |
| NCT00549978Healthy · Korea, Republic of | 4 | Completed | Otsuka | May 2008 | 32 |
| NCT00272454Cerebral Infarction · Korea, Republic of | 4 | Completed | Otsuka | 468 | |
| NCT00234065Cerebral Infarction · Japan | 4 | Completed | Otsuka | Dec 2008 | 2,800 |
| NCT00202020Cerebral Infarction · China | 3 | Completed | Otsuka | 720 | |
| NCT00048776Raynaud Disease · United States | 4 | Completed | Otsuka | 75 | |
| NCT00048763Raynaud Disease · United States | 4 | Completed | Otsuka | 75 |
How it is read
Names in the registry
- “Cilostazol”, 10 entries
- “Cilostazol 100 mg”, 3 entries
- “Cilostazol 50 mg Tablets”, 2 entries
- “Cilostazol Tablet 100 mg”, 2 entries
- “Pletal”, 2 entries
Conditions, from the studies’ own filings
- Intermittent Claudication, 8 studies
- Cerebral Infarction, 5 studies
- Angina Pectoris, Variant, 2 studies
- Raynaud Disease, 2 studies
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.